Agile Therapeutics Price to Sales Ratio 2013-2023 | AGRX
Historical PS ratio values for Agile Therapeutics (AGRX) over the last 10 years. The current P/S ratio for Agile Therapeutics as of May 01, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Agile Therapeutics P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-03-25 |
0.60 |
|
0.05 |
| 2023-12-31 |
1.95 |
$11.22 |
0.17 |
| 2023-09-30 |
2.40 |
$18.79 |
0.13 |
| 2023-06-30 |
2.95 |
$20.59 |
0.14 |
| 2023-03-31 |
11.20 |
$41.05 |
0.27 |
| 2022-12-31 |
11.35 |
$65.14 |
0.17 |
| 2022-09-30 |
14.85 |
$87.09 |
0.17 |
| 2022-06-30 |
58.25 |
$110.47 |
0.53 |
| 2022-03-31 |
419.00 |
$113.65 |
3.69 |
| 2021-12-31 |
976.20 |
$88.04 |
11.09 |
| 2021-09-30 |
1922.20 |
$56.84 |
33.82 |
| 2021-06-30 |
2660.00 |
$29.40 |
90.48 |
| 2021-03-31 |
4160.00 |
$2.65 |
1570.76 |
| 2020-12-31 |
5740.00 |
0 |
0.00 |
| 2020-09-30 |
6080.00 |
0 |
0.00 |
| 2020-06-30 |
5560.00 |
0 |
0.00 |
| 2020-03-31 |
3720.00 |
0 |
0.00 |
| 2019-12-31 |
5000.00 |
0 |
0.00 |
| 2019-09-30 |
2370.00 |
0 |
0.00 |
| 2019-06-30 |
2920.00 |
0 |
0.00 |
| 2019-03-31 |
3020.00 |
0 |
0.00 |
| 2018-12-31 |
1151.80 |
0 |
0.00 |
| 2018-09-30 |
733.00 |
0 |
0.00 |
| 2018-06-30 |
988.00 |
0 |
0.00 |
| 2018-03-31 |
5140.00 |
0 |
0.00 |
| 2017-12-31 |
5380.00 |
0 |
0.00 |
| 2017-09-30 |
8920.00 |
0 |
0.00 |
| 2017-06-30 |
7500.00 |
0 |
0.00 |
| 2017-03-31 |
6410.00 |
0 |
0.00 |
| 2016-12-31 |
11400.00 |
0 |
0.00 |
| 2016-09-30 |
13960.00 |
0 |
0.00 |
| 2016-06-30 |
15220.00 |
0 |
0.00 |
| 2016-03-31 |
12420.00 |
0 |
0.00 |
| 2015-12-31 |
19520.00 |
0 |
0.00 |
| 2015-09-30 |
13480.00 |
0 |
0.00 |
| 2015-06-30 |
17180.00 |
0 |
0.00 |
| 2015-03-31 |
18540.00 |
0 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.003B |
$0.020B |
|
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|
